Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693610 | 0.89 | CRBN (0.40) | CRBNTP53DDB1USP30GPR119 | |
| SCHEMBL2016207 | 0.89 | CRBN (0.40) | CRBNTP53DDB1USP30GPR119 | |
| SCHEMBL2017798 | 0.87 | ESR2 (0.42) | CRBNDDB1USP30GPR119SMARCA2 | |
| SCHEMBL2014200 | 0.87 | ESR2 (0.42) | CRBNDDB1USP30GPR119SMARCA2 | |
| SCHEMBL2015043 | 0.87 | CRBN (0.42) | CRBNTP53DDB1USP30GPR119 | |
| SCHEMBL2015044 | 0.87 | CRBN (0.42) | CRBNTP53DDB1USP30GPR119 | |
| SCHEMBL2018072 | 0.87 | ESR2 (0.42) | CRBNDDB1USP30GPR119SMARCA2 | |
| SCHEMBL2018357 | 0.86 | CNR1 (0.42) | CRBNUSP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL2018339 | 0.86 | FPR2 (0.43) | CRBNUSP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL2017220 | 0.86 | PAK1 (0.42) | CRBNUSP30GPR119SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-05-10 | — | — | US | disclosed |
| US-9701679-B2 | Modulators of 5-HT receptors and methods of use thereof | Abb Vie Deutschland GmbH & Co. KG (DE) | 2017-07-11 | — | — | US | disclosed |
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2421870-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2522671-B1 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-8846663-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2013-11-21 | — | — | US | disclosed |
| US-8546377-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8518933-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2522671-A2 | Modulators of 5-HT receptors and methods of use thereof | Abbott Laboratories (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CRBN 2432/4885TP53 4852/4885DDB1 3918/4885 |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CRBN 2432/4885TP53 4852/4885DDB1 3918/4885 |
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CRBN 2432/4885TP53 4852/4885DDB1 3918/4885 |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CRBN 2432/4885TP53 4852/4885DDB1 3918/4885 |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CRBN 2432/4885TP53 4852/4885DDB1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.